Tapering Fluvoxamine (Luvox)
When discontinuing fluvoxamine, use a gradual dose reduction rather than abrupt cessation to minimize discontinuation syndrome symptoms, which can include dizziness, nausea, sensory disturbances, anxiety, and irritability. 1
Discontinuation Approach
The FDA label for fluvoxamine explicitly states that patients should be monitored for discontinuation symptoms and that "a gradual reduction in the dose rather than abrupt cessation is recommended whenever possible" 1. If intolerable symptoms emerge during tapering, resume the previous dose and then decrease more gradually 1.
Discontinuation Syndrome Risk
Fluvoxamine carries moderate risk for discontinuation syndrome among SSRIs - higher than fluoxetine or citalopram, but lower than paroxetine 2. The syndrome manifests as:
- Physical symptoms: dizziness, fatigue, myalgias, headaches, nausea, vomiting, diarrhea, diaphoresis
- Neurological symptoms: sensory disturbances, paresthesias, vertigo, imbalance
- Psychiatric symptoms: anxiety, irritability, agitation, insomnia 2
These symptoms typically emerge following missed doses or acute discontinuation of shorter-acting SSRIs like fluvoxamine 2.
Practical Tapering Strategy
While the FDA label doesn't specify exact taper rates, applying principles from benzodiazepine tapering guidelines (which share similar discontinuation concerns), a reduction of approximately 25% every 1-2 weeks is a reasonable starting approach 3. For patients on fluvoxamine long-term (≥1 year), even slower tapers of 10% per month may be better tolerated 4.
Specific Recommendations:
- Monitor closely during the first 24-48 hours after each dose reduction 2
- Pause the taper if clinically significant withdrawal symptoms emerge 4
- Slow the taper rate as you reach lower doses, as patients may become more sensitive to reductions 4
- Consider extending intervals between doses once the smallest available dose is reached before complete discontinuation 4
Follow-Up Requirements
Maintain at least monthly contact (in-person or telephone) during the tapering process 4. Team members including nurses and pharmacists can support monitoring through various contact methods 4.
Critical Caveats
- Never discontinue abruptly unless there are life-threatening concerns 4
- Patient agreement is crucial - shared decision-making significantly improves taper success 4
- Screen for emerging psychiatric symptoms including anxiety, depression, or behavioral activation that may be revealed by the taper 4
- If symptoms become intolerable despite slowing the taper, resuming the previous dose and reassessing the approach is appropriate 1
The shorter half-life of fluvoxamine (15 hours average, range 9-28 hours) 5 compared to fluoxetine makes gradual tapering particularly important to avoid discontinuation symptoms.